French researchers have engineered food-grade lactic acid bacteria that secrete the protease inhibitor elafin, a promising therapeutic for intestinal inflammation. Oral delivery of the engineered bacteria reduced inflammation and restored intestinal homeostasis in mouse models of inflammatory bowel disease.